Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 36(5); October 2004
Prev issue Next issue
Review Article
Transcription Factors in the Cellular Signaling Network as Prime Targets of Chemopreventive Phytochemicals
Young-Joon Surh
Cancer Res Treat. 2004;36(5):275-286.   Published online October 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.275
AbstractAbstract PDFPubReaderePub

Accumulating evidence from epidemiologic and laboratory studies support an inverse relationship between a regular consumption of fruits and vegetables and the risk of specific cancers. Numerous phytochemicals derived from edible plants have been reported to possess ability to interfere with a specific stage of carcinogenic process. Multiple mechanisms have been proposed to account for the anti-carcinogenic actions of dietary constituents, but more attention has recently focussed on intracellular signaling cascades as common molecular targets of a wide variety of chemopreventive phytochemicals.

Citations

Citations to this article as recorded by  
  • Role of natural products in breast cancer related symptomology: Targeting chronic inflammation
    Kristina Andrijauskaite, Michael J. Wargovich
    Seminars in Cancer Biology.2022; 80: 370.     CrossRef
  • Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
    Nurul Azwa Abd. Wahab, Nordin H. Lajis, Faridah Abas, Iekhsan Othman, Rakesh Naidu
    Nutrients.2020; 12(3): 679.     CrossRef
  • Morin enhances auranofin anticancer activity by up‐regulation of DR4 and DR5 and modulation of Bcl‐2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells
    Hyun Hwang‐Bo, Won Sup Lee, Arulkumar Nagappan, Hong Jae Kim, Radha Panchanathan, Cheol Park, Seong‐Hwan Chang, Nam Deuk Kim, Sun‐Hee Leem, Young‐Chae Chang, Taeg Kyu Kwon, Jae Hun Cheong, Gon Sup Kim, Jin‐Myung Jung, Sung Chul Shin, Soon Chan Hong, Yung
    Phytotherapy Research.2019; 33(5): 1384.     CrossRef
  • Anti-neuroinflammatory effect of 6,8,1′-tri- O -methylaverantin, a metabolite from a marine-derived fungal strain Aspergillus sp., via upregulation of heme oxygenase-1 in lipopolysaccharide-activated microglia
    Kwan-Woo Kim, Hye Jin Kim, Jae Hak Sohn, Joung Han Yim, Youn-Chul Kim, Hyuncheol Oh
    Neurochemistry International.2018; 113: 8.     CrossRef
  • Quercetin and its metabolites protect hepatocytes against ethanol-induced oxidative stress by activation of Nrf2 and AP-1
    Yoo-Jung Lee, Song-Yi Beak, Inho Choi, Jung-Suk Sung
    Food Science and Biotechnology.2018; 27(3): 809.     CrossRef
  • Role of EGCG in Containing the Progression of Lung Tumorigenesis – A Multistage Targeting Approach
    Sunil Kumar Dhatwalia, Manoj Kumar, Devinder K. Dhawan
    Nutrition and Cancer.2018; 70(3): 334.     CrossRef
  • Attenuation of tert-Butyl Hydroperoxide (t-BHP)-Induced Oxidative Damage in HepG2 Cells by Tangeretin: Relevance of the Nrf2–ARE and MAPK Signaling Pathways
    Fuqiang Liang, Yajing Fang, Weiwei Cao, Zhuo Zhang, Siyi Pan, Xiaoyun Xu
    Journal of Agricultural and Food Chemistry.2018; 66(25): 6317.     CrossRef
  • Asiaticoside Mitigates the Allergic Inflammation by Abrogating the Degranulation of Mast Cells
    Jing Zhi Jiang, Jing Ye, Guang Yu Jin, Hong Mei Piao, Hong Cui, Ming Yu Zheng, Jin Shi Yang, Nan Che, Yun Ho Choi, Liang Chang Li, Guang Hai Yan
    Journal of Agricultural and Food Chemistry.2017; 65(37): 8128.     CrossRef
  • Resveratrol nanoformulation for cancer prevention and therapy
    Imtiaz A. Siddiqui, Vanna Sanna, Nihal Ahmad, Mario Sechi, Hasan Mukhtar
    Annals of the New York Academy of Sciences.2015; 1348(1): 20.     CrossRef
  • Pachymic Acid Induces Apoptosis of EJ Bladder Cancer Cells by DR5 Up-Regulation, ROS Generation, Modulation of Bcl-2 and IAP Family Members
    Jin-Woo Jeong, Won Sup Lee, Se-il Go, Arulkumar Nagappan, Jun Young Baek, Jae-Dong Lee, Su-Jae Lee, Cheol Park, Gi Young Kim, Hye Jung Kim, Gon-Sup Kim, Taeg Kyu Kwon, Chung Ho Ryu, Sung Chul Shin, Yung Hyun Choi
    Phytotherapy Research.2015; 29(10): 1516.     CrossRef
  • Polyphenols Isolated from Allium cepa L. Induces Apoptosis by Induction of p53 and Suppression of Bcl-2 through Inhibiting PI3K/Akt Signaling Pathway in AGS Human Cancer Cells
    Won Sup Lee, Sang Mi Yi, Jeong Won Yun, Ji Hyun Jung, Dong Hoon Kim, Hye Jung Kim, Seong-Hwan Chang, GonSup Kim, Chung Ho Ryu, Sung Chul Shin, Soon Chan Hong, Yung Hyun Choi, Jin-Myung Jung
    Journal of Cancer Prevention.2014; 19(1): 14.     CrossRef
  • Morin, a Flavonoid from Moraceae, Induces Apoptosis by Induction of BAD Protein in Human Leukemic Cells
    Cheol Park, Won Lee, Se-Il Go, Arulkumar Nagappan, Min Han, Su Hong, Gon Kim, Gi Kim, Taeg Kwon, Chung Ryu, Sung Shin, Yung Choi
    International Journal of Molecular Sciences.2014; 16(1): 645.     CrossRef
  • Polyphenols isolated from Allium cepa L. induces apoptosis by suppressing IAP-1 through inhibiting PI3K/Akt signaling pathways in human leukemic cells
    Min Ho Han, Won Sup Lee, Ji Hyun Jung, Jae-Hun Jeong, Cheol Park, Hye Jung Kim, GonSup Kim, Jin-Myung Jung, Taeg Kyu Kwon, Gi-Young Kim, Chung Ho Ryu, Sung Chul Shin, Soon Chan Hong, Yung Hyun Choi
    Food and Chemical Toxicology.2013; 62: 382.     CrossRef
  • Flavonoids from Orostachys japonicus A. Berger Inhibit the Invasion of LnCaP Prostate Carcinoma Cells by Inactivating Akt and Modulating Tight Junctions
    Dong Shin, Won Lee, Ji Jung, Su Hong, Cheol Park, Hye Kim, Gi-Young Kim, Hye Hwang, Gon Kim, Jin-Myung Jung, Chung Ryu, Sung Shin, Soon Hong, Yung Choi
    International Journal of Molecular Sciences.2013; 14(9): 18407.     CrossRef
  • Expression of NSAID-activated gene-1 by EGCG in head and neck cancer: involvement of ATM-dependent p53 expression
    Sung Un Kang, Bok-Soon Lee, Seong-Ho Lee, Seung Joon Baek, Yoo Seob Shin, Chul-Ho Kim
    The Journal of Nutritional Biochemistry.2013; 24(6): 986.     CrossRef
  • Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3′-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6–36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventi
    Lian Chen, Martin Conda-Sheridan, P. V. Narasimha Reddy, Andrew Morrell, Eun-Jung Park, Tamara P. Kondratyuk, John M. Pezzuto, Richard B. van Breemen, Mark Cushman
    Journal of Medicinal Chemistry.2012; 55(12): 5965.     CrossRef
  • Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin
    Hak-Ryul Kim, Sejin Kim, Eun-Jung Kim, Jung-Hyun Park, Sei-Hoon Yang, Eun-Taik Jeong, Channy Park, Myung-Ja Youn, Hong-Seob So, Raekil Park
    Lung Cancer.2008; 60(1): 47.     CrossRef
  • Anticancer activity of sodium caffeate and its mechanism1
    Feng XU, Sheng-hua ZHANG, Rong-guang SHAO, Yong-su ZHEN
    Acta Pharmacologica Sinica.2005; 26(10): 1248.     CrossRef
  • 19,484 View
  • 206 Download
  • 18 Crossref
Close layer
Original Articles
A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting
Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee
Cancer Res Treat. 2004;36(5):287-292.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.287
AbstractAbstract PDFPubReaderePub
Purpose

We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.

Materials and Methods

Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m2 intravenous infusion on day 1 and intravenous ifosfamide 3 g/m2 with Mesna® uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.

Results

One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months).

Conclusion

Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.

Citations

Citations to this article as recorded by  
  • The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
    Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
    Cancer Research and Treatment.2005; 37(6): 339.     CrossRef
  • 9,398 View
  • 52 Download
  • 1 Crossref
Close layer
A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2004;36(5):293-297.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.293
AbstractAbstract PDFPubReaderePub
Purpose

In this phase II study, the efficacy and safety of weekly paclitaxel concomitant with cisplatin and thoracic radiotherapy (TRT) was evaluated in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC).

Materials and Methods

Patients with stage III NSCLC (without pleural effusion or cervical lymphadenopathy) received TRT (63 Gy in 35 fractions over 7 weeks) with concurrent weekly cisplatin 20 mg/m2 and paclitaxel 40 mg/m2/week infused over 3 hours. In patients without evidence of disease progression, the administration of a further 2 cycles of consolidation chemotherapy, consisting of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2, were planned after completion of the TRT.

Results

Between Feb 2000 and Dec 2002, 20 patients were entered into the study; 13 completed all 7 weeks of treatment (median 7.6 weeks; range 3.3 to 9.4). Seven out of 16 (43.8%) objective responses were observed, with 15 (75%) patients experiencing at least one episode of grade 3/4 toxicity. The main toxicities were moderate to severe neutropenia and gastrointestinal toxicity.

Conclusion

The unsatisfactory response rate and the high incidence of grade 3/4 hematologic and non-hematologic toxicities, including 7 early discontinuations of treatment and exceeding the study stopping rules, prompted the early closure of the study. In view of the activity observed, the protocol was amended to protracted continuous infusion paclitaxel, cisplatin and concurrent TRT.

  • 8,325 View
  • 53 Download
Close layer
Prognostic Significance of CD24 Expression in Gastric Carcinoma
Nevine S. Darwish, Min A Kim, Mee Soo Chang, Hye Seung Lee, Byung Lan Lee, Yong Il Kim, Woo Ho Kim
Cancer Res Treat. 2004;36(5):298-302.   Published online October 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.298
AbstractAbstract PDFPubReaderePub
Purpose

The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients.

Materials and Methods

In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression.

Results

One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN+/CD24- cases showed the best survival compared to other groups (p=0.01).

Conclusion

Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Citations

Citations to this article as recorded by  
  • CD24 blockade as a novel strategy for cancer treatment
    Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
    International Immunopharmacology.2023; 121: 110557.     CrossRef
  • Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
    Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
    International Journal of Molecular Sciences.2023; 24(20): 15072.     CrossRef
  • Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
    Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
    Cancer Cell International.2021;[Epub]     CrossRef
  • Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
    Michel Vidal
    Advanced Drug Delivery Reviews.2020; 161-162: 110.     CrossRef
  • CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
    Yang-Hong Ni, Xia Zhao, Wei Wang
    Current Gene Therapy.2020; 20(2): 109.     CrossRef
  • DNA Aptamers for the Malignant Transformation Marker CD24
    Joanna Fafińska, Andreas Czech, Tobias Sitz, Zoya Ignatova, Ulrich Hahn
    Nucleic Acid Therapeutics.2018; 28(6): 326.     CrossRef
  • The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer
    S.M. Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-yin Lam
    Clinical Colorectal Cancer.2017; 16(2): 93.     CrossRef
  • Clinicopathological and Prognostic Value of CD24 Expression in Breast Cancer: A Meta-Analysis
    Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
    The International Journal of Biological Markers.2017; 32(2): 182.     CrossRef
  • CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
    Wenjie Deng, Luo Gu, Xiaojie Li, Jianchao Zheng, Yujie Zhang, Biao Duan, Jie Cui, Jing Dong, Jun Du
    Journal of Translational Medicine.2016;[Epub]     CrossRef
  • CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation
    Jieun Lee, Piera Smeriglio, Jason Dragoo, William J. Maloney, Nidhi Bhutani
    Arthritis Research & Therapy.2016;[Epub]     CrossRef
  • CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
    KEITA TODOROKI, SACHIKO OGASAWARA, JUN AKIBA, MASAMICHI NAKAYAMA, YOSHIKI NAITO, NAOKO SEKI, JINGO KUSUKAWA, HIROHISA YANO
    International Journal of Oncology.2016; 48(1): 99.     CrossRef
  • CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation
    Yao-An Shen, Chia-Yu Wang, Hui-Yen Chuang, John Jeng-Jong Hwang, Wei-Hsin Chi, Chih-Hung Shu, Ching-Yin Ho, Wing-Yin Li, Yann-Jang Chen
    Oncotarget.2016; 7(36): 58351.     CrossRef
  • CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
    Mi Jeong Kwon, Jinil Han, Ji Hyun Seo, Kyoung Song, Hae Min Jeong, Jong-Sun Choi, Yu Jin Kim, Seon-Heui Lee, Yoon-La Choi, Young Kee Shin, Yves St-Pierre
    PLOS ONE.2015; 10(10): e0139112.     CrossRef
  • Expression of CD24, p21, p53, and c‐myc in alpha‐fetoprotein‐producing gastric cancer: Correlation with clinicopathologic characteristics and survival
    Xiaowen Liu, Hongmei Yu, Hong Cai, Yanong Wang
    Journal of Surgical Oncology.2014; 109(8): 859.     CrossRef
  • CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
    Ying-Chao Wang, Ji-Lin Wang, Xuan Kong, Tian-Tian Sun, Hao-Yan Chen, Jie Hong, Jing-Yuan Fang
    Apoptosis.2014; 19(4): 643.     CrossRef
  • CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
    Xueyuan Cao, Donghui Cao, MeiShan Jin, Zhifang Jia, Fei Kong, Hongxi Ma, Yinping Wang, Jing Jiang
    BMC Gastroenterology.2014;[Epub]     CrossRef
  • Hypoxia‐mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion
    Nobuaki Fujikuni, Hideki Yamamoto, Kazuaki Tanabe, Yutaka Naito, Naoya Sakamoto, Yuka Tanaka, Kazuyoshi Yanagihara, Naohide Oue, Wataru Yasui, Hideki Ohdan
    Cancer Science.2014; 105(11): 1411.     CrossRef
  • Clinicopathological and Prognostic Significance of CD24 Overexpression in Patients with Gastric Cancer: A Meta-Analysis
    Jing-Xun Wu, Yuan-Yuan Zhao, Xuan Wu, Han-Xiang An, Yitao Ding
    PLoS ONE.2014; 9(12): e114746.     CrossRef
  • Biomarkers for predicting future metastasis of human gastrointestinal tumors
    Lui Ng, Ronnie Tung Ping Poon, Roberta Pang
    Cellular and Molecular Life Sciences.2013; 70(19): 3631.     CrossRef
  • CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
    Ching-Shya Yong, Chih-Ming Ou Yang, Yenn-Hwei Chou, Chao-Sheng Liao, Chung-Wei Lee, Chin-Cheng Lee
    BMC Gastroenterology.2012;[Epub]     CrossRef
  • PTEN deletion is rare but often homogeneous in gastric cancer
    Sormeh Mina, Benjamin A Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob R Izbicki, Andreas Marx, Phillip R Stahl
    Journal of Clinical Pathology.2012; 65(8): 693.     CrossRef
  • Prognostic significance of loss of c-fos protein in gastric carcinoma
    Seon Pil Jin, Ji Hun Kim, Min A Kim, Han-Kwang Yang, Hee Eun Lee, Hye Seung Lee, Woo Ho Kim
    Pathology & Oncology Research.2007; 13(4): 284.     CrossRef
  • Tissue Array Methods for High-throughput Clinicopathologic Research
    Hye Seung Lee, Woo Ho Kim
    Cancer Research and Treatment.2006; 38(1): 1.     CrossRef
  • Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers
    Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe
    Cancer Research and Treatment.2005; 37(2): 98.     CrossRef
  • Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
    Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel, Glen Kristiansen
    Clinical Cancer Research.2005; 11(18): 6574.     CrossRef
  • 9,443 View
  • 61 Download
  • 25 Crossref
Close layer
Expression of Caspase-3 and c-myc in Non-Small Cell Lung Cancer
Jin young Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Suji Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Seok Jin Kang, Hoon Kyo Kim
Cancer Res Treat. 2004;36(5):303-307.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.303
AbstractAbstract PDFPubReaderePub
Purpose

Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death, but little has been studied clinically on caspase-3 in lung cancer. Increased c-myc expression can result in mitosis or apoptosis, and its contribution to the pathogenesis and prognosis of lung cancer has gained interest. In the present study, the expressions of caspase-3 and c-myc, along with their possible correlations with prognostic variables, were analyzed in resected non-small cell lung carcinomas (NSCLC).

Materials and Methods

Archival tumor tissues from 147 previously untreated NSCLC patients were examined by immunohistochemistry for the expressions of caspase-3 and c-myc proteins. Clinical information was obtained through the computerized retrospective database from the tumor registry.

Results

The expressions of caspase-3 and c-myc were detected in 60 (88/147) and 16% (24/147) of tumors, respectively. No association was found between caspase-3 and c-myc expressions. A multivariate analysis demonstrated the N status and pathologic stage to be significantly correlated with poor survival (p-value=.018 and .002, respectively), but positive expression of caspase-3 was associated with a good prognosis (p=.03).

Conclusion

Our data suggest the involvement of caspase-3 in the tumorigenesis of NSCLC. It is also noteworthy that caspase-3 expression might be a favorable prognostic indicator in these tumors.

Citations

Citations to this article as recorded by  
  • Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells
    Pooyan Honari, Delavar Shahbazzadeh, Mahdi Behdani, Kamran Pooshang Bagheri
    Toxicon.2024; 241: 107673.     CrossRef
  • Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line
    Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
    Current Pharmaceutical Design.2024; 30(17): 1317.     CrossRef
  • Antiproliferative effect of indeno[1,2-d]thiazolo[3,2-a]pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In-silico, In-vitro, and In-vivo study
    Archana Bharti Sonkar, Abhishek Verma, Sneha Yadav, Rohit Kumar, Jyoti Singh, Amit K. Keshari, Soniya Rani, Anurag Kumar, Dharmendra Kumar, Neeraj Kumar Shrivastava, Shubham Rastogi, Mariam K. Alamoudi, Mohd Nazam Ansari, Abdulaziz S. Saeedan, Gaurav Kait
    Cancer Cell International.2024;[Epub]     CrossRef
  • The Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Serum Caspase-3 Level in Patients with Obstructive Sleep Apnea (OSA)
    Mustafa Kemal Kaypak, Ali Nihat Annakkaya, Fatih Davran, Pınar Yıldız Gülhan, Uğur Yüregir
    Sleep and Breathing.2024; 28(4): 1597.     CrossRef
  • The Expression of Caspase-3 and GRIM-19 in Non-mucinous Lung Adenocarcinoma and Their Clinicopathologic Significance
    Alev OK ATILGAN, Merih TEPEOĞLU, Eda YILMAZ AKÇAY, Leyla HASANALİYEVA, Dalokay KILIÇ, Handan ÖZDEMİR
    Düzce Tıp Fakültesi Dergisi.2023; 25(2): 158.     CrossRef
  • Increasing Apoptotic Effect of Cord Blood and Wharton's Jelly-derived Mesenchymal Stem Cells on HT-29
    Figen Abatay-Sel, Ayse Erol, Mediha Suleymanoglu, Gokhan Demirayak, Cigdem Kekik-Cinar, Durdane Serap Kuruca, Fatma Savran-Oguz
    Current Stem Cell Research & Therapy.2023; 18(8): 1133.     CrossRef
  • Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis
    Dingtao Hu, Tingyu Zhang, Ziye Yan, Linlin Wang, Yuhua Wang, Nana Meng, Bizhi Tu, Ying Teng, Zhen Li, Xiaoqi Lou, Yu Lei, Xiaoshuang Ren, Yanfeng Zou, Fang Wang
    Cell Cycle.2022; 21(22): 2444.     CrossRef
  • Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
    Jin Cao, Juan J Gu, Yichen Liang, Buhai Wang
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Global profiling of lncRNAs-miRNAs-mRNAs reveals differential expression of coding genes and non-coding RNAs in the lung of beagle dogs at different stages of Toxocara canis infection
    Wen-Bin Zheng, Yang Zou, Jun-Jun He, Hany M. Elsheikha, Guo-Hua Liu, Min-Hua Hu, Shui-Lian Wang, Xing-Quan Zhu
    International Journal for Parasitology.2021; 51(1): 49.     CrossRef
  • Prognostic Significance of Eight Immune-Related Genes on Survival in Patients with Lung Squamous Cell Carcinoma
    Hansheng Wu, Shujie Huang, Weitao Zhuang, Guibin Qiao
    Biomarkers in Medicine.2021; 15(4): 295.     CrossRef
  • Antitumor Effects of Carvacrol and Thymol: A Systematic Review
    Laeza Alves Sampaio, Lícia Tairiny Santos Pina, Mairim Russo Serafini, Débora dos Santos Tavares, Adriana Gibara Guimarães
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • MYC, MYCL, and MYCN as therapeutic targets in lung cancer
    Daniel Massó-Vallés, Marie-Eve Beaulieu, Laura Soucek
    Expert Opinion on Therapeutic Targets.2020; 24(2): 101.     CrossRef
  • RETRACTED ARTICLE: A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers
    Poonam Parashar, Chandra Bhushan Tripathi, Malti Arya, Jovita Kanoujia, Mahendra Singh, Abhishek Yadav, Shubhini A. Saraf
    Drug Delivery and Translational Research.2019; 9(1): 37.     CrossRef
  • miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9
    Haitao Huang, Yuxuan Wang, Qin Li, Xiaoyan Fei, Haitao Ma, Rongkuan Hu
    Cancer Letters.2019; 446: 81.     CrossRef
  • Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival
    Xuan Pu, Sarah J. Storr, Yimin Zhang, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Stewart G. Martin
    Apoptosis.2017; 22(3): 357.     CrossRef
  • MYC expression correlates with PD-L1 expression in non-small cell lung cancer
    Eun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Chang
    Lung Cancer.2017; 110: 63.     CrossRef
  • Caspase-3 expression in tumorigenesis and prognosis of buccal mucosa squamous cell carcinoma
    Jer-Shyung Huang, Cheng-Mei Yang, Jyh-Seng Wang, Huei-Han Liou, I-Chien Hsieh, Guan-Cheng Li, Sin-Jhih Huang, Chih-Wen Shu, Ting-Ying Fu, Yun-Chung Lin, Luo-Ping Ger, Pei-Feng Liu
    Oncotarget.2017; 8(48): 84237.     CrossRef
  • An epigenetic auto-feedback loop regulates TGF-β type II receptor expression and function in NSCLC
    Shanzhong Yang, Yong-Jig Cho, Lin Jin, Guandou Yuan, Arunima Datta, Phillip Buckhaults, Pran K. Datta
    Oncotarget.2015; 6(32): 33237.     CrossRef
  • Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas
    Yari Ciribilli, Prashant Singh, Reinhard Spanel, Alberto Inga, Jürgen Borlak
    Oncotarget.2015; 6(31): 31569.     CrossRef
  • Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells
    Jui-Chieh Chen, Yen-Hao Su, Ching-Feng Chiu, Yi-Wen Chang, Yang-Hao Yu, Chi-Feng Tseng, Hsin-An Chen, Jen-Liang Su
    Annals of Surgical Oncology.2014; 21(S4): 555.     CrossRef
  • Retracted: MiR‐449c targets c‐Myc and inhibits NSCLC cell progression
    Li-Jun Miao, Shi-Fu Huang, Zhen-Tao Sun, Zeng-Yan Gao, Rui-xia Zhang, Ying Liu, Jing Wang
    FEBS Letters.2013; 587(9): 1359.     CrossRef
  • The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma
    Atsushi Hayashi, Takumi Fumon, Yukari Miki, Hiaki Sato, Tadashi Yoshino, Kiyoshi Takahashi
    Journal of Clinical and Experimental Hematopathology.2013; 53(1): 9.     CrossRef
  • Protein Signature of Lung Cancer Tissues
    Michael R. Mehan, Deborah Ayers, Derek Thirstrup, Wei Xiong, Rachel M. Ostroff, Edward N. Brody, Jeffrey J. Walker, Larry Gold, Thale C. Jarvis, Nebojsa Janjic, Geoffrey S. Baird, Sheri K. Wilcox, Rossella Rota
    PLoS ONE.2012; 7(4): e35157.     CrossRef
  • 10,757 View
  • 70 Download
  • 23 Crossref
Close layer
Effective Inhibition of Cancer Cell Growth by a Novel Tripartite Transfection Complex Containing Ribbon Antisense Molecules to hTR
Jong-Gu Park
Cancer Res Treat. 2004;36(5):308-314.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.308
AbstractAbstract PDFPubReaderePub
Purpose

In the present study, ribbon antisense to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth.

Materials and Methods

Ribbon antisense molecules to the human hTR gene (hTR-RiAS) were constructed and complexed with a short modified peptide and cationic liposomes to improve the cellular uptake of the antisense molecules. The DPL complexes containing hTR-RiAS were transfected into target cancer cells. Various assays were performed to confirm the effects of the hTR-RiAS on the gene expression and cell proliferation.

Results

When cancer cells were treated with hTR-RiAS, the cellular level of hTR mRNA was reduced by more than 95%, as shown by RT-PCR. Further, the telomerase acti vity was also affected by the antisense treatment. In contrast, both mismatched and scrambled oligonucleotides failed to reduce the levels of hTR mRNA and telomerase activity. When checked for cancer cell viability, hTR-RiAS inhibited cell growth by more than 70%, in a very rapid manner. The reduced cell viability was found to be due to apoptosis of cancer cells.

Conclusion

These results show that hTR-RiAS is a powerful anticancer reagent, with the potential for broad efficacy to diverse malignant tumors.

  • 7,358 View
  • 42 Download
Close layer
Activity of Green Tea Polyphenol Epigallocatechin-3-gallate Against Ovarian Carcinoma Cell Lines
Yong Wook Kim, Su Mi Bae, Joon Mo Lee, Sung Eun Namkoong, Sei Jun Han, Byoung Rai Lee, Insu P. Lee, Sang Hee Kim, Young Joo Lee, Chong Kook Kim, Yong-Wan Kim, Woong Shick Ahn
Cancer Res Treat. 2004;36(5):315-323.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.315
AbstractAbstract PDFPubReaderePub
Purpose

A constituent of green tea, (-)-epigallocatechin-3-gallate (EGCG), is known to possess anti-cancer properties. In this study, the time-course of the anticancer effects of EGCG on human ovarian cancer cells were investigated to provide insights into the molecular-level understanding of the growth suppression mechanism involved in EGCG-mediated apoptosis and cell cycle arrest.

Materials and Methods

Three human ovarian cancer cell lines (p53 negative, SKOV-3 cells; mutant type p53, OVCAR-3 cells; and wild type p53, PA-1 cells) were used. The effect of EGCG treatment was studied via a cell count assay, cell cycle analysis, FACS, Western blot and macroarray assay.

Results

EGCG exerts a significant role in suppressing ovarian cancer cell growth, showed dose dependent growth inhibitory effects in each cell line and induced apoptosis and cell cycle arrest. The cell cycle was arrested at the G1 phase by EGCG in SKOV-3 and OVCAR-3 cells.

In contrast, the cell cycle was arrested in the G1/S phase in PA-1 cells. EGCG differentially regulated the expression of genes and proteins (Bax, p21, Retinoblastoma, cyclin D1, CDK4 and Bcl-XL) more than 2 fold, showing a possible gene regulatory role for EGCG. The continual expression in p21WAF1 suggests that EGCG acts in the same way with p53 proteins to facilitate apoptosis after EGCG treatment. Bax, PCNA and Bcl-X are also important in EGCG-mediated apoptosis. In contrast, CDK4 and Rb are not important in ovarian cancer cell growth inhibition.

Conclusion

EGCG can inhibit ovarian cancer cell growth through the induction of apoptosis and cell cycle arrest, as well as in the regulation of cell cycle related proteins. Therefore, EGCG-mediated apoptosis could be applied to an advanced strategy in the development of a potential drug against ovarian cancer.

Citations

Citations to this article as recorded by  
  • Epigallocatechin 3-gallate: From green tea to cancer therapeutics
    Manzar Alam, Sabeeha Ali, Ghulam Md. Ashraf, Anwar L. Bilgrami, Dharmendra Kumar Yadav, Md. Imtaiyaz Hassan
    Food Chemistry.2022; 379: 132135.     CrossRef
  • Synergistic effects of green tea extract and paclitaxel in the induction of mitochondrial apoptosis in ovarian cancer cell lines
    Mohammad Panji, Vahideh Behmard, Zahra Zare, Monireh Malekpour, Hasan Nejadbiglari, Saeede Yavari, Tina Nayerpour dizaj, Azadeh Safaeian, Ali Bakhshi, Omid Abazari, Mojtaba Abbasi, Parisa Khanicheragh, Maryam Shabanzadeh
    Gene.2021; 787: 145638.     CrossRef
  • A Review on the Biological Activity of Camellia Species
    Ana Margarida Teixeira, Clara Sousa
    Molecules.2021; 26(8): 2178.     CrossRef
  • Estrogenic biological activity and underlying molecular mechanisms of green tea constituents
    Ryoiti Kiyama
    Trends in Food Science & Technology.2020; 95: 247.     CrossRef
  • Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
    Rhiane Moody, Kirsty Wilson, Anthony Jaworowski, Magdalena Plebanski
    Cancers.2020; 12(3): 673.     CrossRef
  • Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
    Saleh A. Almatroodi, Ahmad Almatroudi, Amjad Ali Khan, Fahad A. Alhumaydhi, Mohammed A. Alsahli, Arshad Husain Rahmani
    Molecules.2020; 25(14): 3146.     CrossRef
  • The Potential Roles of Epigallocatechin-3-Gallate in the Treatment of Ovarian Cancer: Current State of Knowledge


    Sabrina Bimonte, Marco Cascella
    Drug Design, Development and Therapy.2020; Volume 14: 4245.     CrossRef
  • Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin‐3‐Gallate Against Ovarian Cancer
    S Xinqiang, Z Mu, C Lei, LY Mun
    Clinical and Translational Science.2017; 10(4): 302.     CrossRef
  • Pharmacological profile of green tea and its polyphenols: a review
    Sumit Bansal, Navneet Syan, Pooja Mathur, Shivani Choudhary
    Medicinal Chemistry Research.2012; 21(11): 3347.     CrossRef
  • Plant phytochemicals as new potential drugs for immune disorders and cancer therapy: really a promising path?
    Salvatore Chirumbolo
    Journal of the Science of Food and Agriculture.2012; 92(8): 1573.     CrossRef
  • Green tea for ovarian cancer prevention and treatment: A systematic review of the in vitro, in vivo and epidemiological studies
    Dominique Trudel, David P. Labbé, Isabelle Bairati, Vincent Fradet, Laurent Bazinet, Bernard Têtu
    Gynecologic Oncology.2012; 126(3): 491.     CrossRef
  • Tea Consumption and Epithelial Ovarian Cancer Risk: A Systematic Review of Observational Studies
    Sarah J. Oppeneer, Kim Robien
    Nutrition and Cancer.2011; 63(6): 817.     CrossRef
  • 10,340 View
  • 64 Download
  • 12 Crossref
Close layer
Phenylacetate Induces Growth Inhibition and Apoptosis of Human Osteosarcoma Cells
Jong Hyuk Park, Min Young Park, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Woo Sung Moon, Dong Geun Lee, Myoung Jae Kang
Cancer Res Treat. 2004;36(5):324-329.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.324
AbstractAbstract PDFPubReaderePub
Purpose

Phenylacetate has potent antiproliferative effects in many malignant tumors. However, the exact mechanism as to how phenylacetate induces cell growth arrest remains unclear and very little is known about its effects on human osteosarcoma cells. In this study, we investigated whether phenylacetate is effective against two osteosarcoma cell lines (HOS and U-2 OS) in vitro.

Materials and Methods

The viability of phenylacetate-treated cell lines was assessed by trypan blue exclusion assay, and the cell cycle distribution was measured by flow cytometry. To measure cell apoptosis, poly (ADP-ribose) polymerase cleavage assay and flow cytometry were employed. The expressions of cell cycle-regulatory proteins and the apoptosis-related genes were evaluated by western blot analysis.

Results

Phenylacetate was found to inhibit the growth of osteosarcoma cells, induce cell cycle arrest in the G1 phase, and induce apoptosis. A significant decrease in Bcl-2 expression and a mild up-regulation of Bax were also observed in both phenylacetate-treated cell lines. Reduced phosphorylation of the pRb and the increased expression of p21Cip1 were observed subsequent to treatment with phenylacetate.

Conclusion

These findings support the idea that phenylacetate may be an effective chemotherapeutic agent to be employed in the future against osteosarcoma, because phenylacetate acts to inhibit the growth of osteosarcoma cells through cell cycle arrest and apoptosis.

Citations

Citations to this article as recorded by  
  • Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors
    Daniel J. Burkett, Brittney N. Wyatt, Mallory Mews, Anson Bautista, Ryan Engel, Chris Dockendorff, William A. Donaldson, Martin St. Maurice
    Bioorganic & Medicinal Chemistry.2019; 27(18): 4041.     CrossRef
  • 8,837 View
  • 45 Download
  • 1 Crossref
Close layer
Dexamethasone Inhibits TRAIL- and Anti-cancer Drugs-induced Cell Death in A549 Cells through Inducing NF-κB-independent cIAP2 Expression
Youn Seup Kim, Jae Seuk Park, Young Koo Jee, Kye Young Lee
Cancer Res Treat. 2004;36(5):330-337.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.330
AbstractAbstract PDFPubReaderePub
Purpose

We have examined that dexamethasone inhibits apoptotic cell death of A549 lung epithelial cells through TRAIL and anti-cancer drugs. The purpose of the study is to determine the roles of GR, cIAP and NF-κB in this mechanism.

Materials and Methods

In the A549 lung epithelial cell line, TRAIL, taxol, doxorubicine & gemcitabine were used to investigate cell toxicity. Cells were pretreated 12 hours in advance with dexamethasone. RU486 was pretreated 30 minutes before dexamethasone. Crystal violet assay was used for cell toxicity tests. Apoptosis assay was performed by taking morphologic surveys with fluorescent microscopy after double staining with Hoechst 33342 & propium iodide. RT-PCR was used to investigate the gene expression of cIAP1 & cIAP2 by dexamethasone. Ad-IκB α-SR transduction study was used for the role of NF-κB.

Results

TRAIL and anti-cancer drug-induced apoptosis was partially suppressed in A549 cells pretreated with dexamethasone. The inhibitory effect on cell death disappeared in A549 cells pretreated with RU486. Using RT-PCR, changes of cIAP1 and cIAP2 genes manifestation in A549 cells subsequent to pretreatment with dexamethasone were examined. The results showed an increase in cIAP2 expression during a course of time which was suppressed by RU486 pretreatment. Induction of cIAP2 expression changes by dexamethasone was uniquely observed despite the blockade of NF-κB by Ad-IκBα-SR transduction.

Conclusions

These results suggest that dexamethasone inhibits TRAIL- and anti-cancer drug-induced apoptosis in A549 cells by inducing cIAP2 gene expression through a GR-mediated, NF-κB-independent pathway.

Citations

Citations to this article as recorded by  
  • Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells
    Andrew Thorne, Akanksha Bansal, Amandah Necker-Brown, Mahmoud M. Mostafa, Alex Gao, Andrei Georgescu, Cora Kooi, Richard Leigh, Robert Newton, Aristóbolo M. Silva
    PLOS ONE.2023; 18(6): e0286783.     CrossRef
  • Soluble CD93 in allergic asthma
    Hye Jung Park, Eun-Yi Oh, Hee-Jae Han, Kyung Hee Park, Kyoung-Yong Jeong, Jung-Won Park, Jae-Hyun Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Investigation of New Benzimidazole Derivative Compounds’ Effects on A549 Cell Line
    Gülay Gülbol Duran, Meral Urhan Küçük, Öztekin Algül, Menderes Yusuf Terzi
    Brazilian Archives of Biology and Technology.2020;[Epub]     CrossRef
  • Glucocorticoid-dependent expression of IAP participates in the protection against TNF-mediated cytotoxicity in MCF7 cells
    Irma B. Mitre-Aguilar, Tonatiuh Barrios-Garcia, Victor M. Ruiz-Lopez, Alberto J. Cabrera-Quintero, Nancy R. Mejia-Dominguez, Jose L. Ventura-Gallegos, Daniel Moreno-Mitre, Alejandro Aranda-Gutierrez, Janini Mejia-Rangel, Alma R. Escalona-Guzman, Yanin Cha
    BMC Cancer.2019;[Epub]     CrossRef
  • Epigenetic and Glucocorticoid Receptor-Mediated Regulation of Glutathione Peroxidase 3 in Lung Cancer Cells
    Byung Chull An, Nak-Kyun Jung, Chun Young Park, In-Jae Oh, Yoo-Duk Choi, Jae-Il Park, Seung-won Lee
    Molecules and Cells.2016; 39(8): 631.     CrossRef
  • NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer
    Kate M. Lewis, Elizabeth Harford-Wright, Robert Vink, Mounir N. Ghabriel
    Anti-Cancer Drugs.2013; 24(4): 344.     CrossRef
  • Glucocorticoid Receptor and Histone Deacetylase–2 Mediate Dexamethasone-Induced Repression of MUC5AC Gene Expression
    Yajun Chen, Alan M. Watson, Chad D. Williamson, Michael Rahimi, Chong Liang, Anamaris M. Colberg-Poley, Mary C. Rose
    American Journal of Respiratory Cell and Molecular Biology.2012; 47(5): 637.     CrossRef
  • 11,081 View
  • 74 Download
  • 7 Crossref
Close layer
Case Report
Three Cases of Synchronous Solid Tumor and Multiple Myeloma
Sang Hoon Ji, Joon Oh Park, Jeeyun Lee, Mi Jung Oh, Do Hyoung Lim, Byeong-Bae Park, Keun Woo Park, Se-Hoon Lee, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H Lee, Keunchil Park
Cancer Res Treat. 2004;36(5):338-340.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.338
AbstractAbstract PDFPubReaderePub

The association between a multiple myeloma and a secondary solid tumor is not well established. Some reports showed an increased risk of secondary solid neoplasms in multiple myeloma patients, but others have not. Three cases of the synchronous occurrence of multiple myelomas and solid tumors, namely, a small cell carcinoma of the lung, an adenocarcinoma of the colon and a squamous carcinoma of the pyriform sinus were experienced at our hospital. Therefore, herein is reported the clinical courses and treatment results. The stage of multiple myeloma was Durie-Salmon stage I in all of three cases; therefore, the solid tumors were treated as a primary target because the prognosis of early stage multiple myeloma is generally better than that of advanced solid tumor, while a smoldering or stage I myeloma do not need primary therapy until progression of the multiple myeloma. Two patients died of their solid tumors, but one patient is alive.

Citations

Citations to this article as recorded by  
  • Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
    Koki Tamai, Hajime Hirose, Yo Akazawa, Yukihiro Yoshikawa, Masatoshi Nomura, Hiroshi Takeyama, Masahiro Tokunaga, Mitsuyoshi Tei, Shu Okamura, Yusuke Akamaru
    Surgical Case Reports.2024;[Epub]     CrossRef
  • The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia
    M. F. Petrukhnova, O. O. Voronkova, O. E. Buyanova, O. N. Antyufeeva, A. E. Kamalova, M. V. Kozhevnikova, I. S. Ilgisonis, Yu. N. Belenkov
    Meditsinskiy sovet = Medical Council.2024; (9): 100.     CrossRef
  • Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
    Fang Ye, Huan Wang, Ningning Li, Aijun Liu, Wenming Chen
    Indian Journal of Pathology and Microbiology.2024; 67(2): 390.     CrossRef
  • Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature
    Huan-Huan Dong, Jing Li, Lin Kang, Qiang Wei, Yan Li
    Oncology Letters.2022;[Epub]     CrossRef
  • Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report
    Naoto Ujiie, Yoshitaka Enomoto, Naruhito Takido, Yasushi Kawaharada, Masashi Zuguchi, Yosuke Kubota
    International Journal of Surgery Case Reports.2021; 81: 105834.     CrossRef
  • Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma
    Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song, Qingsong Yin
    Medicine.2017; 96(1): e5787.     CrossRef
  • Drastic Response to Nivolumab in a Case Demonstrating a Rapid Recurrence of Pulmonary Pleomorphic Carcinoma That Developed After Chemotherapy for Comorbid Myeloma Kidney
    Aya Yamamoto, Takashi Iwata, Koji Hashimoto
    Haigan.2017; 57(7): 849.     CrossRef
  • Challenges in managing a patient with multiple primary malignancies
    Nataliya Mar, David Askin, Jerry George, Colette Spaccavento, Robert Graham, Lynn Ratner
    Community Oncology.2012; 9(12): 377.     CrossRef
  • ¿Asociación entre colangiocarcinoma y mieloma múltiple?
    Laura Gómez-Escolar Viejo, Gema Soler Sala, Vanessa Castaño Giraldo, José María Palazón Azorín, Miguel Pérez-Mateo Regadera
    Gastroenterología y Hepatología.2008; 31(6): 402.     CrossRef
  • Synchronous Presentation of Multiple Myeloma and Lung Cancer
    Rishu Agarwal, Ritu Gupta, Archana Bhaskar, Atul Sharma, Sanjay Thulkar, Lalit Kumar
    Journal of Clinical Oncology.2008; 26(35): 5814.     CrossRef
  • 10,016 View
  • 54 Download
  • 10 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP